Review
Open access
Oct 2026
Beyond disease control in chronic myeloid leukemia: Real-world quality of life across TKIs and treatment-free remission
Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a chronic condition with near-normal life expectancy. As patients remain on therapy for years, health-related quality of life (HRQoL) and patient-reported outcomes (PROs) are increasingly important in therapeutic decision-making. H...
S. Buchrits, Giora Sharf, P. Raanani et al.
· Annals of Hematology · 0 citations